Apply to trial NCT06237335

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    They see only the answers needed to decide if you can be screened.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

We save your progress under this email so you can come back later, and the study team uses it to reach you.

By clicking Start, you agree to our terms of service.